Cardiovascular Implantable Electronic Devices -> Monitoring & Outcomes: -> Monitoring & Follow-up D-PO05 - Poster Session V (ID 39) Poster

D-PO05-095 - Risk Of Life-threatening Ventricular Tachycardias And Cardiovascular Death In Amyloidosis Patients - A Very Long-term Cohort Study In Taiwan (ID 547)

 Y. Chen: Nothing relevant to disclose.


Background: Amyloidosis presents various clinical manifestations resulting in a delayed diagnosis and higher cardiovascular mortality risks. Rare studies have reported the long-term absolute risks.
Objective: This study aimed to analyze the epidemiological characteristics and outcomes in amyloidosis cases.
Methods: A total of 12,160 amyloidosis patients were identified using the Taiwan National Health Insurance Research Database (prevalence rate of amyloidosis: 8.62 per 100,000 person-years [PYs]). Controls without amyloidosis at baseline (5-year induction time) were 1:1 matched for the age, sex, and hypertension with a propensity-score to amyloidosis group. The risk of new-onset cardiomyopathy, ventricular tachycardia (VT), and mortality were analyzed.
Results: After a mean follow-up of 11.4±3.56 years, development of cardiomyopathy and related VT events in amyloidosis group was higher than in the controls (9.65 per 10,000 PYs in the amyloidosis group and 7.14 per 10,000 PYs in controls). A Kaplan-Meier survival analysis showed that amyloidosis cases had a significantly poor event-free-survival rates of cardiomyopathy (6 years after diagnosis)/VT (7.5 years after diagnosis) and cardiovascular death (CVD) than controls (Figure). After multivariate adjustment, VT risk was significantly higher in amyloidosis group (HR: 1.61, 95% CI: 1.04-2.48; Table) than controls, as well as CVD risk (HR: 1.47, 95% CI: 1.22-1.78). For amyloidosis cases, they were more likely to develop death risks after incident VT events (HR: 2.82, 95% CI: 1.81-4.39).
Conclusion: Amyloidosis may increase the predisposition to ventricular arrhythmias and risk of CVD during long term follow-up.